Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses PGNY in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named PGNY in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Peter Anevski | $870,000 | $0 | $3,499,980 | $2,099,995 | $736,890 | $0 | $13,747 | $7,220,612 |
| Chief Executive Officer | ||||||||
| Melissa Cummings | 429,546 | 0 | 1,149,993 | 689,988 | 386,550 | 0 | 39,084 | 2,695,161 |
| Chief Operating Officer | ||||||||
| Mark Livingston | 533,000 | 0 | 999,988 | 600,000 | 330,567 | 0 | 16,819 | 2,480,374 |
| Chief Financial Officer | ||||||||
| Geoffrey Clapp | 336,458 | 0 | 749,979 | 450,000 | 226,525 | 0 | 9,666 | 1,772,628 |
| Chief Product Officer | ||||||||
| Allison Swartz | 409,500 | 0 | 624,976 | 375,000 | 225,450 | 0 | 10,225 | 1,645,151 |
| Executive Vice President, General Counsel and Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Peter Anevski | $7,220,612 | $1,361,112 | $1,093,512 | +5,859,500 |
| Melissa Cummings | 2,695,161 | — | — | — |
| Mark Livingston | 2,480,374 | 2,138,369 | 1,398,900 | +342,005 |
| Geoffrey Clapp | 1,772,628 | — | — | — |
| Allison Swartz | 1,645,151 | 1,932,128 | 546,222 | −286,977 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Melissa Cummings | Chief Operating Officer | 2026-04-14 | D | 4,172 | $17 | $70,841 | Common | Form 4 ↗ |
| Melissa Cummings | Chief Operating Officer | 2026-05-19 | D | 9,578 | 25 | 239,450 | Common | Form 4 ↗ |
| Mark Livingston | CHIEF FINANCIAL OFFICER | 2026-05-20 | D | 8,275 | 26 | 211,013 | Common | Form 4 ↗ |
| Elizabeth Bierbower | Director | 2026-05-21 | A | 27,119 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Gordon | Director | 2026-05-21 | A | 30,373 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roger Holstein | Director | 2026-05-21 | A | 4,003 | 12 | 49,997 | Derivative, Class A Common | Form 4 ↗ |
| Roger Holstein | Director | 2026-05-21 | A | 6,792 | 0 | 0 | RSU | Form 4 ↗ |
| Cheryl Scott | Director | 2026-05-21 | A | 27,119 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Norman Payson | Director | 2026-05-21 | A | 5,660 | 0 | 0 | RSU | Form 4 ↗ |
| Jeff Park | Director | 2026-05-21 | A | 31,458 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roger Holstein | Director | 2026-05-21 | A | 29,289 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Gordon | Director | 2026-05-21 | A | 6,792 | 0 | 0 | RSU | Form 4 ↗ |
| Lloyd Dean | Director | 2026-05-21 | A | 28,203 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Bierbower | Director | 2026-05-21 | A | 3,203 | 12 | 40,005 | Derivative, Class A Common | Form 4 ↗ |
| Debra Morris | Director | 2026-05-21 | A | 27,119 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Debra Morris | Director | 2026-05-21 | A | 3,203 | 12 | 40,005 | Derivative, Class A Common | Form 4 ↗ |
| Cheryl Scott | Director | 2026-05-21 | A | 5,660 | 0 | 0 | RSU | Form 4 ↗ |
| Norman Payson | Director | 2026-05-21 | A | 27,119 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeff Park | Director | 2026-05-21 | A | 5,205 | 12 | 65,010 | Derivative, Class A Common | Form 4 ↗ |
| Jeff Park | Director | 2026-05-21 | A | 7,924 | 0 | 0 | RSU | Form 4 ↗ |
| Debra Morris | Director | 2026-05-21 | A | 5,660 | 0 | 0 | RSU | Form 4 ↗ |
| Lloyd Dean | Director | 2026-05-21 | A | 6,792 | 0 | 0 | RSU | Form 4 ↗ |
| Elizabeth Bierbower | Director | 2026-05-21 | A | 5,660 | 0 | 0 | RSU | Form 4 ↗ |
| Norman Payson | Director | 2026-05-21 | A | 3,203 | 12 | 40,005 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Gordon | Director | 2026-05-27 | D | 5,500 | 25 | 137,445 | Common | Form 4 ↗ |
| Kevin Gordon | Director | 2026-05-27 | A | 2,526 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Gordon | Director | 2026-05-27 | D | 2,526 | 0 | 0 | Common | Form 4 ↗ |
| Allison Swartz | EVP, GC | 2026-05-28 | D | 2,398 | 25 | 61,053 | Common | Form 4 ↗ |
| Allison Swartz | EVP, GC | 2026-05-28 | D | 1,352 | 25 | 34,449 | Common | Form 4 ↗ |
| Cheryl Scott | Director | 2026-06-01 | D | 14,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cheryl Scott | Director | 2026-06-01 | A | 14,667 | 13 | 190,671 | Common | Form 4 ↗ |
| Cheryl Scott | Director | 2026-06-01 | D | 7,439 | 26 | 196,278 | Common | Form 4 ↗ |
| Cheryl Scott | Director | 2026-06-01 | D | 7,228 | 26 | 190,675 | Common | Form 4 ↗ |
| Geoffrey Clapp | Chief Product Officer | 2026-06-02 | D | 11,379 | 26 | 290,620 | Common | Form 4 ↗ |
| Geoffrey Clapp | Chief Product Officer | 2026-06-02 | D | 1,530 | 26 | 39,137 | Common | Form 4 ↗ |
| Mark Livingston | CHIEF FINANCIAL OFFICER | 2026-06-02 | D | 279 | 26 | 7,310 | Common | Form 4 ↗ |
| Geoffrey Clapp | Chief Product Officer | 2026-06-02 | D | 12,909 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Livingston | CHIEF FINANCIAL OFFICER | 2026-06-02 | D | 158 | 26 | 4,140 | Common | Form 4 ↗ |
| Geoffrey Clapp | Chief Product Officer | 2026-06-02 | A | 12,909 | 21 | 269,927 | Common | Form 4 ↗ |
| Mark Livingston | CHIEF FINANCIAL OFFICER | 2026-06-03 | D | 1,082 | 25 | 27,180 | Common | Form 4 ↗ |
| Peter Anevski | Director | 2026-06-03 | D | 5,361 | 25 | 134,668 | Common | Form 4 ↗ |
| Allison Swartz | EVP, GC | 2026-06-03 | D | 599 | 25 | 15,023 | Common | Form 4 ↗ |
| Allison Swartz | EVP, GC | 2026-06-03 | D | 1,199 | 25 | 29,999 | Common | Form 4 ↗ |
| Mark Livingston | CHIEF FINANCIAL OFFICER | 2026-06-03 | D | 339 | 25 | 8,472 | Common | Form 4 ↗ |
| Allison Swartz | EVP, GC | 2026-06-03 | D | 676 | 25 | 16,981 | Common | Form 4 ↗ |
| Allison Swartz | EVP, GC | 2026-06-03 | D | 339 | 25 | 8,472 | Common | Form 4 ↗ |
| Mark Livingston | CHIEF FINANCIAL OFFICER | 2026-06-03 | D | 599 | 26 | 15,275 | Common | Form 4 ↗ |
| Mark Livingston | CHIEF FINANCIAL OFFICER | 2026-06-03 | D | 1,918 | 26 | 48,909 | Common | Form 4 ↗ |
| Geoffrey Clapp | Chief Product Officer | 2026-06-17 | D | 819 | 27 | 21,785 | Common | Form 4 ↗ |
| Melissa Cummings | Chief Operating Officer | 2026-07-14 | D | 2,244 | 32 | 70,910 | Common | Form 4 ↗ |
| Melissa Cummings | Chief Operating Officer | 2026-07-14 | D | 1,193 | 32 | 38,152 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Peter Anevski | RSU | — | — | — | 143,179 | — | $699,998 |
| Mark Livingston | OPTION | — | — | — | 600,000 | — | 600,000 |
| Melissa Cummings | RSU | — | — | — | 46,870 | — | 229,978 |
| Geoffrey Clapp | RSU | — | — | — | 28,694 | — | 599,992 |
| Melissa Cummings | OPTION | — | — | — | 689,988 | — | 689,988 |
| Peter Anevski | RSU | — | — | — | 127,272 | — | 2,799,984 |
| Peter Anevski | OPTION | — | — | — | 2,099,995 | — | 2,099,995 |
| Allison Swartz | RSU | — | — | — | 25,563 | — | 124,975 |
| Allison Swartz | OPTION | — | — | — | 375,000 | — | 375,000 |
| Geoffrey Clapp | OPTION | — | — | — | 450,000 | — | 450,000 |
| Allison Swartz | RSU | — | — | — | 22,727 | — | 499,994 |
| Geoffrey Clapp | RSU | — | — | — | 32,276 | — | 149,980 |
| Mark Livingston | RSU | — | — | — | 36,363 | — | 799,986 |
| Mark Livingston | RSU | — | — | — | 40,907 | — | 199,995 |
| Melissa Cummings | RSU | — | — | — | 41,667 | — | 920,000 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Peter Anevski | $3,499,982 | $0 | $2,099,995 | 0.0% |
| Mark Livingston | 999,981 | 0 | 600,000 | 0.0% |
| Melissa Cummings | 1,149,978 | 0 | 689,988 | 0.0% |
| Geoffrey Clapp | 749,972 | 0 | 450,000 | 0.0% |
| Allison Swartz | 624,969 | 0 | 375,000 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Mark Livingston | RSU | 8,435 | — | $216,611 |
| Peter Anevski | Option | 62,500 | 50.35 | — |
| Melissa Cummings | RSU | 31,247 | — | 802,423 |
| Geoffrey Clapp | Option | 39,120 | 20.91 | — |
| Mark Livingston | RSU | 2,185 | — | 56,111 |
| Mark Livingston | RSU | 36,363 | — | 933,802 |
| Melissa Cummings | RSU | 41,667 | — | 1,070,009 |
| Peter Anevski | RSU | 127,272 | — | 3,268,345 |
| Geoffrey Clapp | RSU | 28,694 | — | 736,862 |
| Peter Anevski | RSU | 15,625 | — | 401,250 |
| Allison Swartz | RSU | 15,000 | — | 385,200 |
| Peter Anevski | Option | 174,239 | 22 | — |
| Mark Livingston | Option | 49,783 | 22 | — |
| Allison Swartz | Option | 31,115 | 22 | — |
| Mark Livingston | Option | 62,500 | 39.39 | — |
| Mark Livingston | Option | 6,250 | 36.23 | — |
| Allison Swartz | Option | 43,748 | 36.92 | — |
| Peter Anevski | RSU | 95,453 | — | 2,451,233 |
| Mark Livingston | RSU | 27,272 | — | 700,345 |
| Allison Swartz | RSU | 22,727 | — | 583,629 |
| Allison Swartz | RSU | 17,042 | — | 437,639 |
| Allison Swartz | RSU | 8,435 | — | 216,611 |
| Mark Livingston | Option | 25,310 | 35.48 | — |
| Allison Swartz | Option | 25,310 | 35.48 | — |
| Geoffrey Clapp | RSU | 21,518 | — | 552,582 |
| Melissa Cummings | Option | 56,741 | 22.08 | — |
| Peter Anevski | Option | 200,000 | 39.39 | — |
We have provided compensation packages that we view as fair and competitive relative to our peers and market data and that are designed to incentivize our executives to drive superior performance, as our ability to meet and exceed our business goals depends on the skills and contributions of each executive.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Semler Brossy |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-21 | 61,804,376 | 3,604,955 | 253,817 | 94.12% | Passed |
| 2025 | 2025-05-22 | 24,399,909 | 43,948,036 | 91,631 | 35.65% | Failed |
| 2024 | 2024-05-23 | 82,109,794 | 1,914,294 | 134,521 | 97.57% | Passed |
| 2023 | 2023-05-24 | 27,068,098 | 55,767,673 | 63,987 | 32.65% | Failed |
| 2022 | 2022-05-25 | 77,734,833 | 1,011,237 | 51,041 | 98.65% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-21 | 94.12%a |
| 2025 | 2025-05-22 | 35.65%b |
| 2024 | 2024-05-23 | 97.57%c |
a. Approved under the standard stated in the filing — “Abstentions will be counted as present for purposes of this vote, and therefore will have the same effect as an " AGAINST " vote.”.
b. Approved under the standard stated in the filing — “Abstentions will be counted as present for purposes of this vote, and therefore will have the same effect as an " AGAINST " vote.”.
c. Approved under the standard stated in the filing — “Abstentions will be counted as present for purposes of this vote, and therefore will have the same effect as an " AGAINST " vote.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 46 : 1 |
|---|---|
| CEO total compensation | $7,220,612 |
| Median employee compensation | $156,677 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Kevin GordonIndependent · Audit (Chair) | $52,100 | $167,663 | $456,905 | $0 | $0 | $676,668 |
| Jeff ParkIndependent · Lead Independent Director · Compensation | 73,200 | 195,614 | 392,757 | 0 | -1 | 661,570 |
| Roger HolsteinIndependent · Compensation (Chair) · Nominating and Corporate Governance | 46,000 | 167,663 | 417,476 | 0 | 0 | 631,139 |
| Lloyd DeanIndependent · Audit · Nominating and Corporate Governance (Chair) | 44,500 | 167,663 | 378,025 | 0 | 0 | 590,188 |
| Debra MorrisIndependent · Audit · Newly elected | 38,400 | 0 | 509,561 | 0 | 0 | 547,961 |
| Elizabeth BierbowerIndependent · Compensation · Newly elected | 24,200 | 0 | 517,940 | 0 | 0 | 542,140 |
| Norman PaysonIndependent · Compensation | 42,900 | 139,733 | 338,585 | 0 | 0 | 521,218 |
| Cheryl ScottIndependent · Compensation · Nominating and Corporate Governance | 40,000 | 139,733 | 338,585 | 0 | 0 | 518,318 |
| Fred CohenIndependent · Not standing for re-election · Departed during FY | 19,600 | 0 | 0 | 0 | 0 | 19,600 |
| Peter AnevskiEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| David SchlangerEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | — |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 10,000 / 7,500 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $380,900 |
| Equity awards (grant-date value) | $978,069 |
| All other compensation | $-1 |
| Total cost of the board | $1,358,968 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Progyny names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Progyny.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Masimo Corporation | 2024 | Joe Kiani | $1,209,181 | $10,259,983 | $3,420,105 | $0 | $15,932,345 |
| 2 | Astrana Health, Inc. | 2025 | Brandon Sim | 850,000 | 11,999,980 | 0 | 2,059,125 | 14,930,231 |
| 3 | Evolent Health, Inc. | 2025 | Seth Blackley | 867,068 | 12,699,086 | 0 | 0 | 14,240,154 |
| 4 | R1 RCM Inc. | 2023 | Lee Rivas | 900,000 | 12,240,021 | 0 | 1,015,200 | 14,159,376 |
| 5 | HealthEquity, Inc. | 2026 | Scott Cutler | 775,000 | 12,038,563 | 0 | 767,250 | 13,582,105 |
| 6 | RadNet, Inc. | 2025 | Howard Berger | 3,000,000 | 8,999,966 | 0 | 0 | 12,087,934 |
| 7 | Haemonetics Corporation | 2026 | Christopher Simon | 1,100,008 | 7,561,987 | 1,504,968 | 1,834,250 | 12,044,701 |
| 8 | Premier, Inc. | 2024 | Michael Alkire | 1,095,876 | 8,500,039 | 0 | 1,800,150 | 11,806,381 |
| 9 | Alignment Healthcare, Inc. | 2025 | John Kao | 833,654 | 8,500,014 | 0 | 1,944,495 | 11,278,583 |
| 10 | QuidelOrtho Corporation | 2025 | Brian Blaser | 1,000,000 | 8,965,822 | 0 | 1,274,500 | 11,255,782 |
| 11 | Teladoc Health, Inc. | 2025 | Charles Divita, III | 800,000 | 9,699,996 | 0 | 584,000 | 11,202,996 |
| 12 | Sotera Health Company | 2025 | Michael Petras | 1,130,699 | 8,022,400 | 0 | 1,484,890 | 10,656,063 |
| 13 | Privia Health Group, Inc. | 2025 | Parth Mehrotra | 650,000 | 8,588,373 | 0 | 1,218,750 | 10,472,698 |
| 14 | Azenta, Inc. | 2025 | John Marotta | 900,000 | 8,386,297 | 0 | 1,063,656 | 10,371,414 |
| 15 | NeoGenomics, Inc. | 2025 | Tony Zook | 601,539 | 3,999,997 | 3,998,235 | 513,400 | 9,127,092 |
| 16 | Omnicell, Inc. | 2025 | Randall Lipps | 846,891 | 5,219,576 | 0 | 1,411,485 | 7,531,852 |
| 17 | Progyny | 2025 | Peter Anevski | 870,000 | 3,499,980 | 2,099,995 | 736,890 | 7,220,612 |
| 18 | Certara, Inc. | 2025 | William Feehery | 795,675 | 4,927,502 | 0 | 747,935 | 6,491,387 |
| 19 | Repligen Corporation | 2025 | Olivier Loeillot | 860,000 | 3,374,853 | 1,095,626 | 774,000 | 6,114,771 |
| 20 | CorVel Corporation | 2026 | Michael Combs | 679,327 | 0 | 101,716 | 498,809 | 1,285,043 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Progyny | 85% | RSU 40 · Options 30 · PSU 30 | No | Semler Brossy |
| Alignment Healthcare, Inc. | 200% | RSU 50 · PSU 50 | No | FW Cook |
| Astrana Health, Inc. | 193.8% | PSU 67 · RSU 33 | No | Pearl Meyer |
| Azenta, Inc. | 107.4% | PSU 50 · RSU 50 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
| Certara, Inc. | 94% | PSU 60 · RSU 40 | Yes — annualized total stockholder return (ATSR) | Meridian Compensation Partners |
| CorVel Corporation | Between approximately 28% and 75% of base salary across NEOs% | not disclosed | No | not disclosed |
| Evolent Health, Inc. | 75% | PSU 70 · RSU 30 | No | Exequity |
| Haemonetics Corporation | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| HealthEquity, Inc. | 99% | PSU 60 · RSU 40 | Yes | Semler Brossy |
| Masimo Corporation | 134% | PSU 75 · Options 25 | Yes — Three-Year Cumulative Relative TSR | FW Cook |
| NeoGenomics, Inc. | 60% | RSU 50 · Options 50 | not disclosed | WTW |
| Omnicell, Inc. | 133.3% | RSU 50 · PSU 50 | No | Exequity |
| Premier, Inc. | 109.1% | PSU 60 · RSU 40 | No | Mercer |
| Privia Health Group, Inc. | 150% | PSU 60 · RSU 40 | No | Korn Ferry (through September 2025), WTW (starting September 2025) |
| QuidelOrtho Corporation | 127% | PSU 60 · RSU 40 | Yes — Total Shareholder Return (TSR) | Compensia |
| R1 RCM Inc. | 94% | PSU 75 · RSU 25 | No | SullivanCotter |
| RadNet, Inc. | not disclosed | RSU 100 | No | Pearl Meyer |
| Repligen Corporation | 100% | RSU 50 · PSU 25 · Options 25 | No | Meridian Compensation Partners, LLC |
| Sotera Health Company | 103% | PSU 40 · RSU 40 · Other 20 | No | Exequity |
| Teladoc Health, Inc. | 73% | RSU 50 · PSU 50 | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Peter Anevski | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “2025 Summary Compensation Table”. As printed: 7,220,612. Filing ↗machine: r2 · c48 · span 493966–493975 |
| 2 | Section 01, Melissa Cummings | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “2025 Summary Compensation Table”. As printed: 2,695,161. Filing ↗machine: r11 · c48 · span 523170–523179 |
| 3 | Section 01, Mark Livingston | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “2025 Summary Compensation Table”. As printed: 2,480,374. Filing ↗machine: r5 · c48 · span 503566–503575 |
| 4 | Section 01, Geoffrey Clapp | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “2025 Summary Compensation Table”. As printed: 1,772,628. Filing ↗machine: r12 · c48 · span 526806–526815 |
| 5 | Section 01, Allison Swartz | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “2025 Summary Compensation Table”. As printed: 1,645,151. Filing ↗machine: r8 · c48 · span 513285–513294 |
| 6 | Section 03, Peter Anevski RSU | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t62 · r5 · c22 · span 551044–551051 |
| 7 | Section 03, Mark Livingston OPTION | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t62 · r10 · c22 · span 568516–568523 |
| 8 | Section 03, Melissa Cummings RSU | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t62 · r17 · c22 · span 593081–593088 |
| 9 | Section 03, Geoffrey Clapp RSU | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t62 · r20 · c22 · span 603635–603642 |
| 10 | Section 03, Melissa Cummings OPTION | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t62 · r18 · c22 · span 596540–596547 |
| 11 | Section 03, Peter Anevski RSU | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t62 · r4 · c22 · span 547583–547592 |
| 12 | Section 03, Peter Anevski OPTION | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t62 · r6 · c22 · span 554503–554512 |
| 13 | Section 03, Allison Swartz RSU | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t62 · r13 · c22 · span 579067–579074 |
| 14 | Section 03, Allison Swartz OPTION | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t62 · r14 · c22 · span 582525–582532 |
| 15 | Section 03, Geoffrey Clapp OPTION | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t62 · r22 · c22 · span 610553–610560 |
| 16 | Section 03, Allison Swartz RSU | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t62 · r12 · c22 · span 575610–575617 |
| 17 | Section 03, Geoffrey Clapp RSU | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t62 · r21 · c22 · span 607094–607101 |
| 18 | Section 03, Mark Livingston RSU | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t62 · r8 · c22 · span 561600–561607 |
| 19 | Section 03, Mark Livingston RSU | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t62 · r9 · c22 · span 565058–565065 |
| 20 | Section 03, Melissa Cummings RSU | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t62 · r16 · c22 · span 589622–589629 |
| 21 | Section 07, pay ratio | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “CEO Pay Ratio”. As printed: 46 : 1. Filing ↗machine: span 868868–868870 |
| 22 | Section 08, Kevin Gordon | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Director Compensation”. As printed: 676,668. Filing ↗machine: t88 · r5 · c11 · span 1003498–1003505 |
| 23 | Section 08, Jeff Park | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Director Compensation”. As printed: 661,570. Filing ↗machine: t88 · r8 · c10 · span 1009343–1009350 |
| 24 | Section 08, Roger Holstein | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Director Compensation”. As printed: 631,139. Filing ↗machine: t88 · r6 · c11 · span 1005382–1005389 |
| 25 | Section 08, Lloyd Dean | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Director Compensation”. As printed: 590,188. Filing ↗machine: t88 · r4 · c11 · span 1001616–1001623 |
| 26 | Section 08, Debra Morris | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Director Compensation”. As printed: 547,961. Filing ↗machine: t88 · r7 · c10 · span 1007364–1007371 |
| 27 | Section 08, Elizabeth Bierbower | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Director Compensation”. As printed: 542,140. Filing ↗machine: t88 · r2 · c11 · span 997629–997636 |
| 28 | Section 08, Norman Payson | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Director Compensation”. As printed: 521,218. Filing ↗machine: t88 · r9 · c11 · span 1011232–1011239 |
| 29 | Section 08, Cheryl Scott | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Director Compensation”. As printed: 518,318. Filing ↗machine: t88 · r10 · c11 · span 1013114–1013121 |
| 30 | Section 08, Fred Cohen | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Director Compensation”. As printed: 19,600. Filing ↗machine: t88 · r3 · c2 · span 998511–998517 |
| 31 | Section 08, Peter Anevski | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 32 | Section 08, David Schlanger | DEF 14A | 2026-04-10 | 0001551306-26-000055 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 33 | Section 02, Melissa Cummings 2026-04-14 | Form 4 | 2026-04-16 | 0001551306-26-000059 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Melissa Cummings 2026-05-19 | Form 4 | 2026-05-21 | 0001551306-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Mark Livingston 2026-05-20 | Form 4 | 2026-05-21 | 0001551306-26-000072 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Elizabeth Bierbower 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Kevin Gordon 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Roger Holstein 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000101 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Roger Holstein 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000101 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Cheryl Scott 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Norman Payson 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Jeff Park 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000099 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Roger Holstein 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000101 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Kevin Gordon 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000103 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Lloyd Dean 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Elizabeth Bierbower 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Debra Morris 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Debra Morris 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Cheryl Scott 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Norman Payson 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Jeff Park 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000099 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Jeff Park 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000099 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Debra Morris 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Lloyd Dean 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000105 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Elizabeth Bierbower 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Norman Payson 2026-05-21 | Form 4 | 2026-05-26 | 0001551306-26-000097 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Kevin Gordon 2026-05-27 | Form 4 | 2026-05-29 | 0001551306-26-000112 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Kevin Gordon 2026-05-27 | Form 4 | 2026-05-29 | 0001551306-26-000112 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Kevin Gordon 2026-05-27 | Form 4 | 2026-05-29 | 0001551306-26-000112 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Allison Swartz 2026-05-28 | Form 4 | 2026-06-01 | 0001551306-26-000114 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Allison Swartz 2026-05-28 | Form 4 | 2026-06-01 | 0001551306-26-000114 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Cheryl Scott 2026-06-01 | Form 4 | 2026-06-03 | 0001551306-26-000118 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Cheryl Scott 2026-06-01 | Form 4 | 2026-06-03 | 0001551306-26-000118 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Cheryl Scott 2026-06-01 | Form 4 | 2026-06-03 | 0001551306-26-000118 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Cheryl Scott 2026-06-01 | Form 4 | 2026-06-03 | 0001551306-26-000118 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Geoffrey Clapp 2026-06-02 | Form 4 | 2026-06-03 | 0001551306-26-000117 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Geoffrey Clapp 2026-06-02 | Form 4 | 2026-06-03 | 0001551306-26-000117 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Mark Livingston 2026-06-02 | Form 4 | 2026-06-03 | 0001551306-26-000120 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Geoffrey Clapp 2026-06-02 | Form 4 | 2026-06-03 | 0001551306-26-000117 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Mark Livingston 2026-06-02 | Form 4 | 2026-06-03 | 0001551306-26-000120 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Geoffrey Clapp 2026-06-02 | Form 4 | 2026-06-03 | 0001551306-26-000117 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Mark Livingston 2026-06-03 | Form 4 | 2026-06-05 | 0001551306-26-000126 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Peter Anevski 2026-06-03 | Form 4 | 2026-06-05 | 0001551306-26-000124 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Allison Swartz 2026-06-03 | Form 4 | 2026-06-05 | 0001551306-26-000125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Allison Swartz 2026-06-03 | Form 4 | 2026-06-05 | 0001551306-26-000125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Mark Livingston 2026-06-03 | Form 4 | 2026-06-05 | 0001551306-26-000126 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Allison Swartz 2026-06-03 | Form 4 | 2026-06-05 | 0001551306-26-000125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Allison Swartz 2026-06-03 | Form 4 | 2026-06-05 | 0001551306-26-000125 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Mark Livingston 2026-06-03 | Form 4 | 2026-06-05 | 0001551306-26-000126 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Mark Livingston 2026-06-03 | Form 4 | 2026-06-05 | 0001551306-26-000126 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Geoffrey Clapp 2026-06-17 | Form 4 | 2026-06-23 | 0001551306-26-000129 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Melissa Cummings 2026-07-14 | Form 4 | 2026-07-16 | 0001551306-26-000131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Melissa Cummings 2026-07-14 | Form 4 | 2026-07-16 | 0001551306-26-000131 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 06, 2026 vote | Form 8-K | 2026-05-27 | 0001551306-26-000109 | Item 5.07 · say-on-pay result. As reported: 94.12% (votes for as printed: 61,804,376). Filing ↗ |
| 85 | Section 06, 2025 vote | Form 8-K | 2025-05-28 | 0001551306-25-000131 | Item 5.07 · say-on-pay result. As reported: 35.65% (votes for as printed: 24,399,909). Filing ↗ |
| 86 | Section 06, 2024 vote | Form 8-K | 2024-05-29 | 0001551306-24-000128 | Item 5.07 · say-on-pay result. As reported: 97.57% (votes for as printed: 82,109,794). Filing ↗ |
| 87 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 88 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 89 | Section 09b board cost (computed) | Computed | — | computed | Cash 380,900 + equity 978,069 + all other -1 = 1,358,968, summed across the director compensation table rows.machine: formula: Σ = 1,358,968 |
| 90 | Masimo Corporation, Section 10b CEO total | DEF 14A | 2025-03-26 | 0001104659-25-027887 | CEO total compensation as printed in Masimo Corporation's own proxy. As printed: 15,932,345. Filing ↗machine: span 1265493–1265503 |
| 91 | Astrana Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001104659-26-044536 | CEO total compensation as printed in Astrana Health, Inc.'s own proxy. As printed: 14,930,231. Filing ↗machine: span 525189–525199 |
| 92 | Evolent Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177267 | CEO total compensation as printed in Evolent Health, Inc.'s own proxy. As printed: 14,240,154. Filing ↗machine: r3 · c20 · span 908544–908555 |
| 93 | R1 RCM Inc., Section 10b CEO total | DEF 14A | 2024-04-12 | 0001628280-24-015923 | CEO total compensation as printed in R1 RCM Inc.'s own proxy. As printed: 14,159,376. Filing ↗machine: span 758069–758079 |
| 94 | HealthEquity, Inc., Section 10b CEO total | DEF 14A | 2026-05-13 | 0001428336-26-000022 | CEO total compensation as printed in HealthEquity, Inc.'s own proxy. As printed: 13,582,105. Filing ↗machine: r3 · c21 · span 892475–892485 |
| 95 | RadNet, Inc., Section 10b CEO total | DEF 14A | 2026-04-20 | 0001683168-26-003086 | CEO total compensation as printed in RadNet, Inc.'s own proxy. As printed: 12,087,934. Filing ↗machine: t93 · r1 · c26 · span 428610–428620 |
| 96 | Haemonetics Corporation, Section 10b CEO total | DEF 14A | 2026-06-09 | 0000313143-26-000074 | CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. Filing ↗machine: span 718173–718183 |
| 97 | Premier, Inc., Section 10b CEO total | DEF 14A | 2024-10-21 | 0001193125-24-240399 | CEO total compensation as printed in Premier, Inc.'s own proxy. As printed: 11,806,381. Filing ↗machine: span 1173351–1173361 |
| 98 | Alignment Healthcare, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001628280-26-027058 | CEO total compensation as printed in Alignment Healthcare, Inc.'s own proxy. As printed: 11,278,583. Filing ↗machine: r2 · c21 · span 656828–656838 |
| 99 | QuidelOrtho Corporation, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001906324-26-000018 | CEO total compensation as printed in QuidelOrtho Corporation's own proxy. As printed: 11,255,782. Filing ↗machine: r4 · c24 · span 760612–760622 |
| 100 | Teladoc Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001477449-26-000020 | CEO total compensation as printed in Teladoc Health, Inc.'s own proxy. As printed: 11,202,996. Filing ↗machine: t167 · r2 · c16 · span 1057476–1057486 |
| 101 | Sotera Health Company, Section 10b CEO total | DEF 14A | 2026-04-08 | 0001104659-26-040937 | CEO total compensation as printed in Sotera Health Company's own proxy. As printed: 10,656,063. Filing ↗machine: span 996859–996869 |
| 102 | Privia Health Group, Inc., Section 10b CEO total | DEF 14A | 2026-04-02 | 0001193125-26-138997 | CEO total compensation as printed in Privia Health Group, Inc.'s own proxy. As printed: 10,472,698. Filing ↗machine: t166 · r3 · c39 · span 538905–538915 |
| 103 | Azenta, Inc., Section 10b CEO total | DEF 14A | 2025-12-18 | 0001140361-25-046064 | CEO total compensation as printed in Azenta, Inc.'s own proxy. As printed: 10,371,414. Filing ↗machine: r2 · c22 · span 1247118–1247129 |
| 104 | NeoGenomics, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001077183-26-000014 | CEO total compensation as printed in NeoGenomics, Inc.'s own proxy. As printed: 9,127,092. Filing ↗machine: r2 · c45 · span 869460–869469 |
| 105 | Omnicell, Inc., Section 10b CEO total | DEF 14A | 2026-04-13 | 0001104659-26-042631 | CEO total compensation as printed in Omnicell, Inc.'s own proxy. As printed: 7,531,852. Filing ↗machine: r1 · c47 · span 668949–668958 |
| 106 | Progyny (subject), Section 10b CEO total | DEF 14A | 2026-04-10 | 0001551306-26-000055 | CEO total compensation as printed in Progyny's own proxy. As printed: 7,220,612. Filing ↗machine: r2 · c48 · span 493966–493975 |
| 107 | Certara, Inc., Section 10b CEO total | DEF 14A | 2026-04-03 | 0001104659-26-039372 | CEO total compensation as printed in Certara, Inc.'s own proxy. As printed: 6,491,387. Filing ↗machine: r1 · c42 · span 883232–883241 |
| 108 | Repligen Corporation, Section 10b CEO total | DEF 14A | 2026-04-02 | 0001193125-26-140115 | CEO total compensation as printed in Repligen Corporation's own proxy. As printed: 6,114,771. Filing ↗machine: t16 · r4 · c2 · span 577065–577074 |
| 109 | CorVel Corporation, Section 10b CEO total | DEF 14A | 2026-06-26 | 0001193125-26-285509 | CEO total compensation as printed in CorVel Corporation's own proxy. As printed: 1,285,043. Filing ↗machine: span 348386–348395 |
| 110 | Section 10a, Masimo Corporation reciprocity | DEF 14A | — | 0001104659-25-027887 | Masimo Corporation's most recent proxy was read; its disclosed peer group does not include Progyny. Filing ↗ |
| 111 | Section 10a, Repligen Corporation reciprocity | DEF 14A | — | 0001193125-26-140115 | Repligen Corporation's most recent proxy was read; its disclosed peer group does not include Progyny. Filing ↗ |
| 112 | Section 10a, Certara, Inc. reciprocity | DEF 14A | — | 0001104659-26-039372 | Certara, Inc.'s most recent proxy was read; its disclosed peer group does not include Progyny. Filing ↗ |
| 113 | Section 10a, Evolent Health, Inc. reciprocity | DEF 14A | — | 0001193125-26-177267 | Evolent Health, Inc.'s most recent proxy was read; its disclosed peer group does not include Progyny. Filing ↗ |
| 114 | Section 10a, Haemonetics Corporation reciprocity | DEF 14A | — | 0000313143-26-000074 | Haemonetics Corporation's most recent proxy was read; its disclosed peer group does not include Progyny. Filing ↗ |
| 115 | Section 10a, Sotera Health Company reciprocity | DEF 14A | — | 0001104659-26-040937 | Sotera Health Company's most recent proxy was read; its disclosed peer group does not include Progyny. Filing ↗ |
| 116 | Section 10a, NeoGenomics, Inc. reciprocity | DEF 14A | — | 0001077183-26-000014 | NeoGenomics, Inc.'s most recent proxy was read; its disclosed peer group does not include Progyny. Filing ↗ |
| 117 | Section 10a, Omnicell, Inc. reciprocity | DEF 14A | — | 0001104659-26-042631 | Omnicell, Inc.'s most recent proxy was read; its disclosed peer group does not include Progyny. Filing ↗ |
| 118 | Section 10a, QuidelOrtho Corporation reciprocity | DEF 14A | — | 0001906324-26-000018 | QuidelOrtho Corporation's most recent proxy was read; its disclosed peer group does not include Progyny. Filing ↗ |
| 119 | Section 10a, RadNet, Inc. reciprocity | DEF 14A | — | 0001683168-26-003086 | RadNet, Inc.'s most recent proxy was read; its disclosed peer group does not include Progyny. Filing ↗ |
| 120 | Section 10a, Teladoc Health, Inc. reciprocity | DEF 14A | — | 0001477449-26-000020 | Teladoc Health, Inc.'s most recent proxy was read; its disclosed peer group does not include Progyny. Filing ↗ |
| 121 | Section 10a, Alignment Healthcare, Inc. reciprocity | DEF 14A | — | 0001628280-26-027058 | Alignment Healthcare, Inc.'s most recent proxy was read; its disclosed peer group does not include Progyny. Filing ↗ |
| 122 | Section 10a, HealthEquity, Inc. reciprocity | DEF 14A | — | 0001428336-26-000022 | HealthEquity, Inc. names Progyny in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 123 | Section 10a, Premier, Inc. reciprocity | DEF 14A | — | 0001193125-24-240399 | Premier, Inc.'s most recent proxy was read; its disclosed peer group does not include Progyny. Filing ↗ |
| 124 | Section 10a, Azenta, Inc. reciprocity | DEF 14A | — | 0001140361-25-046064 | Azenta, Inc.'s most recent proxy was read; its disclosed peer group does not include Progyny. Filing ↗ |
| 125 | Section 10a, Privia Health Group, Inc. reciprocity | DEF 14A | — | 0001193125-26-138997 | Privia Health Group, Inc.'s most recent proxy was read; its disclosed peer group does not include Progyny. Filing ↗ |
| 126 | Section 10a, R1 RCM Inc. reciprocity | DEF 14A | — | 0001628280-24-015923 | R1 RCM Inc.'s most recent proxy was read; its disclosed peer group does not include Progyny. Filing ↗ |